Skip to main content
Erschienen in: Familial Cancer 2/2018

03.07.2017 | Short Communication

Issues related to family history of cancer at the end of life: a palliative care providers’ survey

verfasst von: Catherine Gonthier, Sylvie Pelletier, Pierre Gagnon, Ana Marin, Jocelyne Chiquette, Bruno Gagnon, Louis Roy, Jude Emmanuel Cléophat, Yann Joly, Michel Dorval

Erschienen in: Familial Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Addressing the concerns of end-of-life patients or their relatives about their family history of cancer could benefit patients and family members. Little is known about how palliative care providers respond to these concerns. The purpose of this pilot study was to assess palliative care providers’ knowledge about familial and hereditary cancers and explore their exposure to patients’ and relatives’ concerns about their family history of cancer, and their self-perceived ability to deal with such concerns. A cross-sectional survey was conducted in the Quebec City (Canada) catchment area among palliative care professionals. Fifty-eight palliative care professionals working in hospice, home care and hospital-based palliative care units completed the questionnaire. All physicians and 63% of nurses occasionally addressed concerns of patients and relatives about their family history of cancer, but they reported a low confidence level in responding to such concerns. They also showed knowledge gaps in defining features of a significant family history of cancer, and most (78%) would welcome specific training on the matter. Our findings highlight the relevance of offering education and training opportunities about familial cancers and associated risks to palliative care providers. The needs and concerns of end-of-life patients and their families need to be explored to ensure palliative care providers can adequately assist patients and their relatives about their family history of cancer. Ethical implications should be considered.
Literatur
1.
Zurück zum Zitat Offit K, Garber JE, Grady M, Greene MH, Gruber S, Peshkin B, Rodriguez-Bigas M, Trimbath J, Weitzeil J (2004) ASCO curriculum: cancer genetics & cancer predisposition testing, 2nd edn. ASCO Publishing, Alexandria Offit K, Garber JE, Grady M, Greene MH, Gruber S, Peshkin B, Rodriguez-Bigas M, Trimbath J, Weitzeil J (2004) ASCO curriculum: cancer genetics & cancer predisposition testing, 2nd edn. ASCO Publishing, Alexandria
2.
Zurück zum Zitat Foulkes WD (2008) Inherited susceptibility to common cancers. New Eng J Med 359(20):2143–2153CrossRefPubMed Foulkes WD (2008) Inherited susceptibility to common cancers. New Eng J Med 359(20):2143–2153CrossRefPubMed
3.
Zurück zum Zitat Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161CrossRefPubMed Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161CrossRefPubMed
4.
Zurück zum Zitat Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND et al (2014) American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol 32(8):833–840CrossRefPubMedPubMedCentral Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND et al (2014) American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol 32(8):833–840CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Wood ME, Stockdale A, Flynn BS (2008) Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract 25(5):334–340CrossRefPubMedPubMedCentral Wood ME, Stockdale A, Flynn BS (2008) Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract 25(5):334–340CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Quillin JM, Bodurtha JN, Smith TJ (2008) Genetics assessment at the end of life: suggestions for implementation in clinic and future research. J Palliat Med 11(3):451–458CrossRefPubMed Quillin JM, Bodurtha JN, Smith TJ (2008) Genetics assessment at the end of life: suggestions for implementation in clinic and future research. J Palliat Med 11(3):451–458CrossRefPubMed
7.
Zurück zum Zitat Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, Lu KH (2011) A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Fam Cancer 10(2):193–197CrossRefPubMedPubMedCentral Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, Lu KH (2011) A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Fam Cancer 10(2):193–197CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J et al. (2011) Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract 9:2CrossRefPubMedPubMedCentral Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J et al. (2011) Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract 9:2CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bottorff JL, Blaine S, Carroll JC, Esplen MJ, Evans J, Nicolson Klimek ML et al (2005) The educational needs and professional roles of Canadian physicians and nurses regarding genetic testing and adult onset hereditary disease. Community Genet 8:80–87CrossRefPubMed Bottorff JL, Blaine S, Carroll JC, Esplen MJ, Evans J, Nicolson Klimek ML et al (2005) The educational needs and professional roles of Canadian physicians and nurses regarding genetic testing and adult onset hereditary disease. Community Genet 8:80–87CrossRefPubMed
10.
Zurück zum Zitat Lakhani NS, Weir J, Allford A, Kai J, Barwell JG (2013) Could triaging family history of cancer during palliative care enable earlier genetic counseling intervention? Palliat Med 16(11):1350–1355CrossRef Lakhani NS, Weir J, Allford A, Kai J, Barwell JG (2013) Could triaging family history of cancer during palliative care enable earlier genetic counseling intervention? Palliat Med 16(11):1350–1355CrossRef
11.
Zurück zum Zitat Lapointe J, Côté C, Bouchard K, Godard B, Simard J, Dorval M (2013) Life events may contribute to family communication about cancer risk following BRCA1/2 testing. J Genet Couns 22:249–257CrossRefPubMed Lapointe J, Côté C, Bouchard K, Godard B, Simard J, Dorval M (2013) Life events may contribute to family communication about cancer risk following BRCA1/2 testing. J Genet Couns 22:249–257CrossRefPubMed
Metadaten
Titel
Issues related to family history of cancer at the end of life: a palliative care providers’ survey
verfasst von
Catherine Gonthier
Sylvie Pelletier
Pierre Gagnon
Ana Marin
Jocelyne Chiquette
Bruno Gagnon
Louis Roy
Jude Emmanuel Cléophat
Yann Joly
Michel Dorval
Publikationsdatum
03.07.2017
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0021-y

Weitere Artikel der Ausgabe 2/2018

Familial Cancer 2/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.